Is IPSC or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% ArriVent BioPharma N/A -48.98% -45.44%

Does the media favor IPSC or AVBP?

In the previous week, Century Therapeutics had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for Century Therapeutics and 2 mentions for ArriVent BioPharma. Century Therapeutics' average media sentiment score of 0.00 equaled ArriVent BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ORIC or IPSC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Century Therapeutics N/A -49.89% -37.42%

Does the media prefer ORIC or IPSC?

In the previous week, Oric Pharmaceuticals had 11 more articles in the media than Century Therapeutics. MarketBeat recorded 14 mentions for Oric Pharmaceuticals and 3 mentions for Century Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.30 beat Century Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GLUE or IPSC?

In the previous week, Monte Rosa Therapeutics had 15 more articles in the media than Century Therapeutics. MarketBeat recorded 18 mentions for Monte Rosa Therapeutics and 3 mentions for Century Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.04 beat Century Therapeutics' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ABSI or IPSC?

In the previous week, Century Therapeutics had 1 more articles in the media than Absci. MarketBeat recorded 3 mentions for Century Therapeutics and 2 mentions for Absci. Absci's average media sentiment score of 0.00 equaled Century Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IPSC or MLTX more profitable?

Century Therapeutics' return on equity of -49.89% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Century Therapeutics (IPSC) Competitors

$1.98 -0.03 (-1.25%)

As of 01:35 PM Eastern

Compare

IPSC vs. AVBP, ORIC, GLUE, ABSI, and MLTX

Should you buy Century Therapeutics stock or one of its competitors? MarketBeat compares Century Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Century Therapeutics include ArriVent BioPharma (AVBP), Oric Pharmaceuticals (ORIC), Monte Rosa Therapeutics (GLUE), Absci (ABSI), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "biotechnology" industry.

How does Century Therapeutics compare to ArriVent BioPharma?

Century Therapeutics (NASDAQ:IPSC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Century Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.26	-$9.58M	-$1.14	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Century Therapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ArriVent BioPharma's return on equity of -48.98% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
ArriVent BioPharma	N/A	-48.98%	-45.44%

In the previous week, Century Therapeutics had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for Century Therapeutics and 2 mentions for ArriVent BioPharma. Century Therapeutics' average media sentiment score of 0.00 equaled ArriVent BioPharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics presently has a consensus price target of $4.75, indicating a potential upside of 140.51%. ArriVent BioPharma has a consensus price target of $44.83, indicating a potential upside of 47.21%. Given Century Therapeutics' higher possible upside, research analysts clearly believe Century Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Century Therapeutics beats ArriVent BioPharma on 9 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Oric Pharmaceuticals presently has a consensus target price of $19.45, suggesting a potential upside of 47.56%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 140.51%. Given Century Therapeutics' higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Century Therapeutics	$109.16M	3.26	-$9.58M	-$1.14	N/A

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oric Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Oric Pharmaceuticals' return on equity of -35.35% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Century Therapeutics	N/A	-49.89%	-37.42%

In the previous week, Oric Pharmaceuticals had 11 more articles in the media than Century Therapeutics. MarketBeat recorded 14 mentions for Oric Pharmaceuticals and 3 mentions for Century Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.30 beat Century Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oric Pharmaceuticals beats Century Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Monte Rosa Therapeutics presently has a consensus price target of $28.50, suggesting a potential upside of 81.99%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 140.51%. Given Century Therapeutics' higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Monte Rosa Therapeutics had 15 more articles in the media than Century Therapeutics. MarketBeat recorded 18 mentions for Monte Rosa Therapeutics and 3 mentions for Century Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.04 beat Century Therapeutics' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Century Therapeutics	N/A	-49.89%	-37.42%

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Monte Rosa Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Century Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	10.80	-$38.63M	-$1.76	N/A
Century Therapeutics	$109.16M	3.26	-$9.58M	-$1.14	N/A

Summary

Monte Rosa Therapeutics beats Century Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Century Therapeutics compare to Absci?

Absci (NASDAQ:ABSI) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Century Therapeutics has a net margin of 0.00% compared to Absci's net margin of -6,450.76%. Century Therapeutics' return on equity of -49.89% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-6,450.76%	-66.32%	-57.01%
Century Therapeutics	N/A	-49.89%	-37.42%

Absci presently has a consensus target price of $13.43, indicating a potential upside of 48.79%. Century Therapeutics has a consensus target price of $4.75, indicating a potential upside of 140.51%. Given Century Therapeutics' higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Century Therapeutics had 1 more articles in the media than Absci. MarketBeat recorded 3 mentions for Century Therapeutics and 2 mentions for Absci. Absci's average media sentiment score of 0.00 equaled Century Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

52.1% of Absci shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Absci has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

Century Therapeutics has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	502.50	-$115.18M	-$0.83	N/A
Century Therapeutics	$109.16M	3.26	-$9.58M	-$1.14	N/A

Summary

Century Therapeutics beats Absci on 8 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to MoonLake Immunotherapeutics?

Century Therapeutics (NASDAQ:IPSC) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Century Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.26	-$9.58M	-$1.14	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than Century Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 3 mentions for Century Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.59 beat Century Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Century Therapeutics' return on equity of -49.89% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Century Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Century Therapeutics presently has a consensus price target of $4.75, indicating a potential upside of 140.51%. MoonLake Immunotherapeutics has a consensus price target of $24.21, indicating a potential upside of 41.25%. Given Century Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Century Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Century Therapeutics beats MoonLake Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPSC vs. The Competition

Export

Metric	Century Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$355.83M	$3.72B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.73	9.08	269.97	24.82
Price / Sales	3.26	1,268.38	650.66	108.09
Price / Cash	150.38	44.95	28.89	37.44
Price / Book	1.09	17.65	11.26	6.44
Net Income	-$9.58M	-$13.25M	$3.45B	$347.27M
7 Day Performance	-0.25%	5.33%	3.62%	2.55%
1 Month Performance	-12.22%	-1.83%	-0.56%	-1.02%
1 Year Performance	289.32%	61.05%	77.38%	23.33%

Century Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPSC Century Therapeutics	1.2196 of 5 stars	$1.98 -1.3%	$4.75 +140.5%	+294.2%	$355.83M	$109.16M	N/A	170	Upcoming Earnings
AVBP ArriVent BioPharma	1.7252 of 5 stars	$31.16 +5.1%	$44.83 +43.9%	+71.4%	$1.45B	N/A	N/A	40	Positive News Upcoming Earnings Gap Up
ORIC Oric Pharmaceuticals	2.302 of 5 stars	$13.64 +28.7%	$19.27 +41.3%	+46.1%	$1.41B	N/A	N/A	80	Earnings Report Upcoming Earnings Analyst Forecast
GLUE Monte Rosa Therapeutics	2.9349 of 5 stars	$16.22 +5.5%	$30.67 +89.1%	+262.6%	$1.37B	$123.67M	N/A	90	Earnings Report Analyst Forecast Gap Up
ABSI Absci	2.6052 of 5 stars	$8.52 +7.4%	$13.43 +57.7%	+214.4%	$1.33B	$2.80M	N/A	210	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPSC) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Century Therapeutics (IPSC) Competitors

IPSC vs. AVBP, ORIC, GLUE, ABSI, and MLTX

How does Century Therapeutics compare to ArriVent BioPharma?

Summary

How does Century Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Century Therapeutics compare to Monte Rosa Therapeutics?

Summary

How does Century Therapeutics compare to Absci?

Summary

How does Century Therapeutics compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Century Therapeutics (IPSC) Competitors

IPSC vs. AVBP, ORIC, GLUE, ABSI, and MLTX

How does Century Therapeutics compare to ArriVent BioPharma?

Which has higher valuation and earnings, IPSC or AVBP?

Which has more risk & volatility, IPSC or AVBP?

Do institutionals and insiders hold more shares of IPSC or AVBP?

Is IPSC or AVBP more profitable?

Does the media favor IPSC or AVBP?

Do analysts prefer IPSC or AVBP?

Summary

How does Century Therapeutics compare to Oric Pharmaceuticals?

Do analysts rate ORIC or IPSC?

Which has preferable valuation & earnings, ORIC or IPSC?

Do institutionals & insiders have more ownership in ORIC or IPSC?

Which has more risk & volatility, ORIC or IPSC?

Is ORIC or IPSC more profitable?

Does the media prefer ORIC or IPSC?

Summary

How does Century Therapeutics compare to Monte Rosa Therapeutics?

Do analysts prefer GLUE or IPSC?

Does the media favor GLUE or IPSC?

Is GLUE or IPSC more profitable?

Do institutionals and insiders have more ownership in GLUE or IPSC?

Which has more volatility and risk, GLUE or IPSC?

Which has better valuation & earnings, GLUE or IPSC?

Summary

How does Century Therapeutics compare to Absci?

Is ABSI or IPSC more profitable?

Do analysts rate ABSI or IPSC?

Does the media prefer ABSI or IPSC?

Do institutionals & insiders believe in ABSI or IPSC?

Which has more volatility & risk, ABSI or IPSC?

Which has stronger valuation & earnings, ABSI or IPSC?

Summary

How does Century Therapeutics compare to MoonLake Immunotherapeutics?

Which has preferable earnings & valuation, IPSC or MLTX?

Does the media favor IPSC or MLTX?

Is IPSC or MLTX more profitable?

Which has more volatility and risk, IPSC or MLTX?

Do analysts recommend IPSC or MLTX?

Do insiders and institutionals believe in IPSC or MLTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools